BRAF and melanoma: Therefore, the standard treatment of NRAS-mutant patients is currently the same as for BRAF wild-type melanoma; anti-PD-1 based immunotherapy is the first-line therapy, and the second-line therapy includes anti-CTLA-4, cytotoxic chemotherapy, or drugs in experimental trials.